Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Factbox: Launches of Novo Nordisk's weight-loss drug Wegovy
07:08am, Monday, 04'th Sep 2023
Novo Nordisk is pushing ahead with the launches of weight-loss drug Wegovy in Europe even as it struggles to keep up with demand. The Danish drugmaker is working to convince European governments and i
Weight-Loss Drug Wegovy Launches In U.K. As Shares Of Drugmaker Novo Nordisk Hit New Peak
06:16am, Monday, 04'th Sep 2023
In August, Novo Nordisk's CEO said it could “take quite some years” for the company to meet soaring demand for the popular drug.
Novo Nordisk launches weight-loss drug Wegovy in UK
02:03am, Monday, 04'th Sep 2023
Novo Nordisk launched its weight-loss injection Wegovy in Britain on Monday, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to keep
Novo Nordisk briefly becomes Europe's No1 as investors binge on weight-loss stocks
08:12am, Friday, 01'st Sep 2023
Novo Nordisk (NYSE:NVO) became Europe's largest company for a short time today as investors continued to pile into the Danish drugmaker following the recent trial of fat-busting drug Wegovy. Shares in
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
07:01am, Friday, 01'st Sep 2023
Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen In
Ozempic could be the next target of Medicare drug price negotiations – here's why
11:42am, Thursday, 31'st Aug 2023
Wall Street analysts expect Ozempic to be selected for price negotiations in 2025 due to the amount of money Medicare Part D already spends on the drug.
Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
03:17pm, Wednesday, 30'th Aug 2023
Novo Nordisk is making strides in the weight loss and diabetes care markets, with strong financial performance and a diverse product portfolio. The company faces competition from Eli Lilly's GLP-1 tre
Novo Nordisk CEO: Not exactly clear yet what Medicare price negotiations will do for financials
12:09pm, Wednesday, 30'th Aug 2023
Lars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Squawk on the Street' to discuss what's known about the White House's negotiations for specific drug prices, long-term worries about suppressed R&D
Wegovy Maker Novo Nordisk Buys Embark Biotech to Boost Edge in Weight Loss Treatments
11:55am, Wednesday, 30'th Aug 2023
Wegovy maker Novo Nordisk (NVO) agreed to buy Embark Biotech for €15 million ($16 million) in cash upfront, in a move that could boost Novo Nordisk's portfolio of weight loss treatments. In addition
What the medicare decision means for pharma stocks
06:37pm, Tuesday, 29'th Aug 2023
Jared Holz, Mizuho, joins 'Fast Money' to talk the Biden Administration unveiling the first 10 drugs subject to medicare price negotiations and how pharma stocks are responding.
Cantor's Louise Chen breaks down new Medicare drug pricing negotiations
03:02pm, Tuesday, 29'th Aug 2023
Louise Chen, Cantor Fitzgerald, joins 'Power Lunch' to discuss Medicare drug priced ahead of Biden's news conference on the negotiations.
10 Drugs Selected for Medicare Price Reduction
12:01pm, Tuesday, 29'th Aug 2023
We're getting Case-Shiller home price numbers ahead of the opening bell this morning, but there's not enough time to dig into it. Give us till this afternoon to speak about these.
Insulins and blood thinners among first 10 drugs up for Medicare price negotiations
10:47am, Tuesday, 29'th Aug 2023
The Biden administration has revealed the first 10 prescription drugs that will be subject to price negotiations between manufacturers and the U.S. health program Medicare with the aim of reducing ou
Does the Red-Hot Weight-Loss Market Make This Pharmaceutical Stock a Buy?
09:53am, Tuesday, 29'th Aug 2023
Novo Nordisk has seen huge success with Ozempic, which treats type 2 diabetes. Now, it has followed up with a similar drug, Wegovy, for addressing obesity.
Why Wegovy's Sales Potential Could Be Massively Understated
05:47am, Tuesday, 29'th Aug 2023
Wegovy may generate more than $4 billion in revenue this year for Novo Nordisk. A recent study showed the weight-loss drug can also help people bring down their risk of heart attack or stroke.
